GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer ...

GSK plc GSK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

GSK had great expectations for Blenrep after its accelerated FDA approval in 2020 as a fourth-line or later treatment for multiple myeloma, which came crashing down with the failure of the DREAMM ...

GSK’sGSK-0.32 % decrease; red down pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return ...

Meanwhile, GSK finds itself in a curious position with Blenrep. Back in November 2022, GSK pulled Blenrep from the U.S. market a little more than two weeks after the ADC had failed to top a ...

The Blenrep results presented Monday are from a Phase 3 test, DREAMM-7, that enrolled nearly 500 patients whose multiple myeloma relapsed or was refractory to at least one earlier line of therapy.

GSK's Blenrep approved in the U.K. for multiple myeloma after strong phase 3 data showing improved survival in DREAMM-7 and DREAMM-8 trials.